Registration No. 333 -
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT UNDER THE
SECURITIES ACT OF 1933
ABBVIE INC.
(Exact name of registrant as specified in its charter)
Delaware | 32-0375147 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(847) 932-7900
(Address of Principal Executive Offices, Including Zip Code)
AbbVie Deferred Compensation Plan
AbbVie
Deferred Compensation Plan Plus
(Full title of the plan)
Perry C. Siatis, Esq.
Executive Vice President, General Counsel and Secretary
AbbVie Inc.
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(847)
932-7900
(Name, address and telephone number, including area code, of agent for service)
Copies to:
Sophia Hudson, P.C.
Zoey Hitzert
Kirkland & Ellis LLP
601 Lexington Avenue
New York, New York 10022
(212) 446-4800
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer | x | Accelerated filer | ¨ | |
Non-accelerated filer | ¨ | Smaller reporting company | ¨ | |
Emerging growth company | ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.
EXPLANATORY NOTE
AbbVie Inc. (the “Registrant”) is filing this Registration Statement on Form S-8 (this “Registration Statement”) to register additional deferred compensation obligations of the Registrant under (i) the AbbVie Deferred Compensation Plan (the “DCP”) and (ii) the AbbVie Deferred Compensation Plan Plus (together with the DCP, the “Plans”).
This Registration Statement relates to securities of the same class as those registered under a prior Registration Statement and is being filed in accordance with General Instruction E to Form S-8 regarding the registration of additional securities. Pursuant to such instruction, this Registration Statement incorporates by reference the contents of the Registration Statement on Form S-8, File No. 333-268192, filed by the Registrant on November 4, 2022, relating to the Plans.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
* | Filed herewith. |
2 |
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in North Chicago, Illinois, on November 4, 2024.
AbbVie Inc. | ||
By: | /s/ Scott T. Reents | |
Name: Scott T. Reents | ||
Title: Executive Vice President, Chief Financial Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Robert A. Michael, Perry C. Siatis, and Scott T. Reents, and each of them, with full power of substitution and full power to act without the others, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file this Registration Statement, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated.
Signature | Title | Date | ||
/s/ Robert A. Michael | Chief Executive Officer and Director | November 4, 2024 | ||
Robert A. Michael | (Principal Executive Officer) | |||
/s/ Scott T. Reents | Executive Vice President, Chief Financial Officer | November 4, 2024 | ||
Scott T. Reents | (Principal Financial Officer) | |||
/s/ Kevin K. Buckbee | Senior Vice President, Controller | November 4, 2024 | ||
Kevin K. Buckbee | (Principal Accounting Officer) | |||
/s/ Richard A. Gonzalez | Executive Chairman of the Board | November 4, 2024 | ||
Richard A. Gonzalez | ||||
/s/ Robert J. Alpern, M.D. | Director | November 4, 2024 | ||
Robert J. Alpern, M.D. | ||||
/s/ Roxanne S. Austin | Director | November 4, 2024 | ||
Roxanne S. Austin |
3 |
/s/ William H.L. Burnside | Director | November 4, 2024 | ||
William H.L. Burnside | ||||
/s/ Jennifer L. Davis | Director | |||
Jennifer L. Davis | November 4, 2024 | |||
/s/ Thomas C. Freyman | Director | November 4, 2024 | ||
Thomas C. Freyman | ||||
/s/ Brett J. Hart | Director | November 4, 2024 | ||
Brett J. Hart | ||||
/s/ Melody B. Meyer | Director | November 4, 2024 | ||
Melody B. Meyer | ||||
/s/ Susan E. Quaggin, M.D. | Director | November 4, 2024 | ||
Susan E. Quaggin, M.D. | ||||
/s/ Edward J. Rapp | Director | November 4, 2024 | ||
Edward J. Rapp | ||||
/s/ Rebecca B. Roberts | Director | November 4, 2024 | ||
Rebecca B. Roberts | ||||
/s/ Glenn F. Tilton | Director | November 4, 2024 | ||
Glenn F. Tilton | ||||
/s/ Frederick H. Waddell | Director | November 4, 2024 | ||
Frederick H. Waddell |
4 |